PCSK9 antagonists
The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
1. A pharmaceutical composition comprising a therapeutically effective amount of an isolated antibody comprising a heavy chain variable region (VH) complementary determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:8, 59, or 60, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:61 or 9, a VH CDR3 having the amino acid sequence shown in SEQ ID NO:10, a light chain variable region (VL) CDR1 having the amino acid sequence shown in SEQ ID NO:11, a VL CDR2 having the amino acid sequence shown in SEQ ID NO:12, and a VL CDR3 having the amino acid sequence shown in SEQ ID NO:13.
2. The pharmaceutical composition of claim 1 , further comprising a therapeutically effective amount of a statin.
3. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable carrier, excipient, or stabilizer, wherein the carrier, excipient, or stabilizer is selected from the group consisting of a chelating agent, a sugar, a buffer, and a surfactant.
4. The pharmaceutical composition of claim 1 , wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises the amino acid sequence of SEQ ID NO: 54 and the VL region comprises the amino acid sequence of SEQ ID NO: 53.
5. An aqueous formulation comprising:
about 1 mg/ml to about 200 mg/ml of an antagonist antibody that specifically binds to PCSK9 comprising amino acid sequence of SEQ ID NO: 188;
about 1 mM to about 100 mM of a buffer;
about 0.01 mg/ml to about 10 mg/ml of a surfactant; and
about 100 mM to about 400 mM of a stabilizer;
wherein the formulation has a pH at about 5.0 to about 6.5, and wherein the antibody comprises a heavy chain variable region (VH) complementary determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:8, 59, or 60, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:61 or 9, a VH CDR3 having the amino acid sequence shown in SEQ ID NO:10, a light chain variable region (VL) CDR1 having the amino acid sequence shown in SEQ ID NO:11, a VL CDR2 having the amino acid sequence shown in SEQ ID NO:12, and a VL CDR3 having the amino acid sequence shown in SEQ ID NO:13.
6. The formulation of claim 5 , wherein the antibody comprises a VH and a VL region, wherein the VH region comprises the amino acid sequence of SEQ ID NO: 54 and the VL region comprises the amino acid sequence of SEQ ID NO: 53.
7. The formulation of claim 5 , wherein the buffer is a histidine buffer.
8. The formulation of claim 7 , wherein the surfactant is polysorbate 80.
9. The formulation of claim 8 , wherein the stabilizer is trehalose.
10. The formulation of claim 9 , wherein the chelating agent is EDTA.
11. An aqueous formulation comprising:
about 1 mg/ml to about 200 mg/ml of an antagonist antibody that specifically binds to PCSK9 comprising amino acid sequence of SEQ ID NO: 188;
about 1 mM to about 100 mM of a buffer;
about 0.01 mg/ml to about 10 mg/ml of a surfactant;
about 100 mM to about 400 mM of a stabilizer; and
about 0.01 mM to about 1.0 mM of a chelating agent;
wherein the formulation has a pH at about 5.0 to about 6.5, and wherein the antibody comprises a heavy chain variable region (VH) complementary determining region one (CDR1) having the amino acid sequence shown in SEQ ID NO:8, 59, or 60, a VH CDR2 having the amino acid sequence shown in SEQ ID NO:61 or 9, a VH CDR3 having the amino acid sequence shown in SEQ ID NO:10, a light chain variable region (VL) CDR1 having the amino acid sequence shown in SEQ ID NO:11, a VL CDR2 having the amino acid sequence shown in SEQ ID NO:12, and a VL CDR3 having the amino acid sequence shown in SEQ ID NO:13.